SOURCE: Vestaron Corporation
KALAMAZOO, MI--(Marketwire - Aug 14, 2012) - Vestaron Corporation announced today that it will describe milestone progress on malarial vector control research in a presentation at the 244th American Chemical Society National Meeting and Exposition in Philadelphia. The ACS National Meeting and Exposition is the world's largest gathering of chemistry professionals, attracting more than 12,000 chemists, chemical engineers, academicians, graduate and postdoctoral students, and other related professionals.
The presentation, entitled "Imitating insecticidal spider peptides; In silico screening and optimization of a heterocyclic family of mosquitocides," will be presented on Tuesday, August 21nd at 1:30 pm. by Robert M. Kennedy, PhD, Chief Scientific Officer of Vestaron. The presentation will disclose a new chemotype of insecticidal triazines.
"The rapid progression of our synthetic insecticide discovery program is a validation of the Vestaron technology platform," Kennedy said. "This milestone demonstrates the Vestaron scientific team's ability to efficiently translate an understanding of the structure of natural peptides into a pipeline of synthetic insecticide development candidates."
Vestaron has developed a technology platform grounded in structural biology traversing to structure-based design in the development of synthetic insecticides based on natural peptides isolated from predators of insects. Vestaron is concurrently progressing a pipeline of peptide products, the most advanced of which, is under regulatory review at the US EPA. These peptides have new modes of action, and are selected to be harmless to non-target species, including humans. For more information visit www.vestaron.com.
Vestaron Corporation, a venture-backed agricultural biotechnology company based in Kalamazoo, MI, has been funded in this work by a grant from the Foundation for the National Institutes of Health through the Vector-Based Transmission of Control: Discovery Research (VCTR) program of the Grand Challenges in Global Health initiative.
Forward Looking Statements
Certain statements in this announcement contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors.